Henry Schein, Inc. $HSIC Shares Sold by Nuance Investments LLC

Nuance Investments LLC cut its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 61.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 314,208 shares of the company’s stock after selling 494,249 shares during the quarter. Henry Schein makes up approximately 2.1% of Nuance Investments LLC’s portfolio, making the stock its 17th largest holding. Nuance Investments LLC owned approximately 0.26% of Henry Schein worth $20,854,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. lifted its stake in Henry Schein by 26.0% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 16,627 shares of the company’s stock worth $1,104,000 after purchasing an additional 3,433 shares in the last quarter. M.D. Sass LLC grew its holdings in shares of Henry Schein by 21.3% during the 3rd quarter. M.D. Sass LLC now owns 1,314,603 shares of the company’s stock worth $87,250,000 after purchasing an additional 230,407 shares during the period. Sentry Investment Management LLC increased its position in shares of Henry Schein by 132.1% during the third quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock valued at $59,000 after acquiring an additional 515 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in Henry Schein by 14.7% in the 3rd quarter. Envestnet Asset Management Inc. now owns 104,740 shares of the company’s stock valued at $6,952,000 after purchasing an additional 13,441 shares during the last quarter. Finally, State of Wyoming grew its stake in shares of Henry Schein by 54.2% in the third quarter. State of Wyoming now owns 10,220 shares of the company’s stock valued at $678,000 after buying an additional 3,594 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Trading Up 3.5%

Shares of NASDAQ:HSIC opened at $79.72 on Monday. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $81.35. The company’s 50 day moving average is $76.40 and its two-hundred day moving average is $70.98. The company has a market cap of $9.38 billion, a PE ratio of 25.23, a P/E/G ratio of 2.37 and a beta of 0.88. The company has a current ratio of 1.40, a quick ratio of 0.79 and a debt-to-equity ratio of 0.54.

Analyst Ratings Changes

HSIC has been the topic of a number of recent research reports. Barrington Research set a $79.00 price target on shares of Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Barclays began coverage on shares of Henry Schein in a research note on Monday, December 8th. They set an “overweight” rating and a $86.00 target price on the stock. Evercore raised their price target on shares of Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Finally, Wells Fargo & Company increased their price objective on Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 5th. Five equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $76.42.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.